ArticleJournal of thoracic disease2024
Identification of prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 106 patients.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global trends, risk factors, and therapeutic associations of fungal pulmonary infections in lung cancer: A systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The morbidity and mortality of chronic pulmonary aspergillosis (CPA) are very high. We aimed to investigate the prognostic factors of patients with CPA, especially focusing on the underlying pulmonary disease and the probable co-infection of bacterial. Methods: We retrospectively analyzed 106 CPA patients from November 2019 to August 2023. We collected the patient's clinical medical records. Kaplan-Meier survival curves were used to analyze patient survival; log-rank tests were utilized to compare survival among groups. Univariate and multivariate Cox proportional hazards regression analyses were applied for identification of potential prognostic factors. Results: The mean age at the time of diagnosis was 60.3±14.8 years; 74 (69.8%) patients were male. There was significant difference between patients with and without lung cancer (P<0.001), and with and without emphysema (P=0.02). Other prognosis factors associated with mortality were as follows: smoking (P=0.04), cough (P=0.01), simultaneous discovery with Gram-negative bacteria (P=0.02), and hypoalbuminemia (P=0.001) in log-rank tests. Multivariate Cox regression analyses showed that emphysema [hazard ratio (HR), 4.107; 95% confidence interval (CI): 1.414-11.933; P=0.009] and lung cancer (HR, 8.511; 95% CI: 2.494-29.047; P<0.001) were identified as independent predictors of mortality. The 1- and 3-year survival rates with emphysema were 75.2% and 64.9%, respectively, whereas those for patients without emphysema were 92.6% and 85.9%, respectively. Conclusions: In the current study, emphysema and lung cancer were independent predictors of mortality. Therefore, we should pay attention to the patients with these underlying lung diseases in order to improve the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.